Drug intelligence / Profile preview

R&D711

Development stage: Unknown
Lead developer: Bostal Pharma
Modality: Small Molecules
Administration: Intramuscular

Overview

R&D711 is a long-acting injectable (LAI) formulation of an antipsychotic medication being developed by Bostal Pharma for the treatment of schizophrenia and bipolar I disorder. Developed via the 505(b)(2) regulatory pathway, R&D711 is designed as a 6-month (6M) depot injection, utilizing Bostal's proprietary drug delivery technologies to provide sustained therapeutic drug levels and improve patient adherence. The product is part of a series of long-acting formulations in Bostal's pipeline and is currently in early-stage development, with Phase 1 clinical trials projected to begin in 2027 and an NDA submission targeted for 2031.

Other names: R&D711 LAI 6M

Beyond the preview

Go deeper on R&D711.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on R&D711.

Explore the full profile